Editor's Note: On the morning of September 17, 2026, the plenary session of the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) grandly opened at Shandong Hall, Shandong Building, in Jinan. Chaired by Professor Zefei Jiang, President-Elect of CSCO, the session featured Professor Shukui Qin, Chair of the CSCO Steering Committee, announcing the recipients of the society's awards. The honors showcased the year's achievements in original research, standardized cancer care, and the development of emerging talent in Chinese clinical oncology.

Professor Shukui Qin announces the award recipients.

2026 CSCO Annual Achievement Award

  • Academician Jia Fan — Zhongshan Hospital, Fudan University
  • Professor Li Zhang — Sun Yat-sen University Cancer Center
  • Professor Jun Guo — Peking University Cancer Hospital
  • Professor Shun Lu — Shanghai Chest Hospital, Shanghai Jiao Tong University
  • Professor Jie Wang — Cancer Hospital, Chinese Academy of Medical Sciences

2026 Innovation Research Award: Ten Clinical Studies Selected

1. PANKU-Esophagus01: A multicenter, randomized, open-label phase III clinical study of lunvenlatug vedotin versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma

  • First author: Professor Zhihao Lu, Peking University Cancer Hospital
  • Corresponding author: Professor Lin Shen, Peking University Cancer Hospital

2. A Phase Ib/IIa Clinical Study of the Safety, Tolerability, and Dose Exploration of the National Class 1.1 Innovative Drug Qian Ceng Zhi Su Pian in Patients With Advanced Malignant Solid Tumors

  • First author: Professor Fan Yang, School of Public Health, Nanjing Medical University
  • Corresponding author: Professor Shukui Qin, School of Public Health, Nanjing Medical University

3. OptiTROP-Breast05: Updated results from the phase II study of sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer (a/m TNBC)

  • First and corresponding author: Professor Yongmei Yin, Jiangsu Province Hospital

4. MIZAR-003: Efficacy and safety of autologous tumor-infiltrating lymphocytes (GC101 TIL) in patients with advanced melanoma resistant to PD-1 antibodies: A multicenter, open-label, randomized controlled phase II clinical trial

  • First and corresponding author: Lu Si, Peking University Cancer Hospital

5. Symbiotic-Lung-01: A phase III clinical study comparing the PD-1/VEGF bispecific antibody PF-08634404 with pembrolizumab plus platinum-based chemotherapy as first-line treatment for locally advanced or metastatic non-small cell lung cancer

  • First and corresponding author: Professor Caicun Zhou, Shanghai East Hospital, Tongji University

6. PANKU-Breast02: A randomized phase III clinical study of lunvenlatug vedotin versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer

  • First and corresponding author: Professor Jiong Wu, Fudan University Shanghai Cancer Center

7. ARTEMIS-008: Primary results from the phase III ARTEMIS-008 study of risvutatug rezetecan versus topotecan as second-line treatment for small cell lung cancer

  • First author: Professor Jie Wang, Cancer Hospital, Chinese Academy of Medical Sciences
  • Corresponding author: Academician Jinming Yu, Cancer Hospital, Shandong First Medical University

8. Symbiotic-Lung-04: A phase II/III clinical study of the PD-1/VEGF bispecific antibody PF-08634404 plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer

  • First and corresponding author: Professor Yilong Wu, Guangdong Provincial People’s Hospital

9. TORCHLIGHT: A multimodal unified survival ensemble model (MUSE-i) for predicting survival benefit from immunotherapy in triple-negative breast cancer (TNBC): An analysis from the TORCHLIGHT study

  • First author: Professor Jianbin Li, Fifth Medical Center of the Chinese PLA General Hospital
  • Corresponding author: Professor Zefei Jiang, Fifth Medical Center of the Chinese PLA General Hospital

10. A Nectin-4-Targeted Peptide–Drug Conjugate, SC-101, for Advanced Urothelial Carcinoma: Updated Results From a Phase I Dose-Escalation and Dose-Expansion Study

  • First and corresponding author: Professor Juan Li, Peking University Cancer Hospital

2026 Outstanding Paper Award

First Prize: Three Studies

1. ASTRUM-LC01: Efficacy and safety of consolidation serplulimab following hypofractionated concurrent chemoradiotherapy for limited-stage small cell lung cancer: A nationwide multicenter phase II clinical study

  • First author: Professor Yuqi Wu, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  • Corresponding author: Professor Nan Bi, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

2. MIZAR-003: Efficacy and safety of modified autologous tumor-infiltrating lymphocyte therapy (GC101 TIL) in patients with advanced melanoma resistant to PD-1 antibodies: A multicenter, open-label, randomized controlled pivotal phase II clinical trial

  • First and corresponding author: Professor Lu Si, Peking University Cancer Hospital

3. KEYNOTE-590: Pembrolizumab Plus Chemotherapy in Participants From China With Advanced Esophageal Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-590 Study

  • First and corresponding author: Professor Lin Shen, Peking University Cancer Hospital

Second Prize: Five Studies

1. CheckMate 9DW: Nivolumab (NIVO) plus ipilimumab (IPI) versus lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): Four-year follow-up of the Chinese patient population and an exploratory analysis based on liver function

  • First and corresponding author: Professor Shukui Qin, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine

2. STELLAR II: Short-Course Radiotherapy-Based Total Neoadjuvant Therapy With or Without a PD-1 Inhibitor in pMMR Locally Advanced Rectal Cancer: Short-Term Results from a Randomized Phase 3 Trial

  • First author: Professor Haoyue Li, Cancer Hospital, Chinese Academy of Medical Sciences
  • Corresponding author: Professor Jing Jin, Cancer Hospital, Chinese Academy of Medical Sciences

3. CHRYSALIS-2: Overall Survival With First-Line Amivantamab Plus Lazertinib In Advanced NSCLC Harboring Atypical EGFR Mutations: Extended Follow-Up From CHRYSALIS-2

  • First and corresponding author: Professor Yongsheng Wang, West China Hospital, Sichuan University

4. Subcutaneous Envafolimab Plus Gemcitabine and Oxaliplatin (GEMOX) Versus GEMOX Alone as First-Line Treatment for Chinese Patients With Advanced Biliary Tract Cancer: A Randomized, Open-Label, Multicenter Phase III Registration Trial

  • First and corresponding author: Professor Shukui Qin, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine

5. SKYSCRAPER-07: Atezolizumab With or Without Tiragolumab In Patients With Unresectable Esophageal Squamous Cell Carcinoma That Has Not Progressed Following Definitive Concurrent Chemoradiotherapy: The SKYSCRAPER-07 China Subpopulation Analysis

  • First author: Professor Lühua Wang, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Hospital
  • Corresponding author: Academician Ruihua Xu, Sun Yat-sen University Cancer Center

Third Prize: Ten Studies

1. DESTINY-Gastric04: Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive unresectable or metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Results from the DESTINY-Gastric04 study

  • First author: Professor Bo Liu, Cancer Hospital, Shandong First Medical University
  • Corresponding author: Professor Lin Shen, Peking University Cancer Hospital

2. KEYNOTE-859: Long-Term Follow-Up of the KEYNOTE-859 China Subgroup: Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for Previously Untreated Advanced or Metastatic HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma

  • First and corresponding author: Professor Shukui Qin, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine

3. EV-302: Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 3.5-Year Follow-Up and Response Adapted Treatment from the Phase 3 EV-302 Study

  • First and corresponding author: Professor Xinan Sheng, Peking University Cancer Hospital

4. Multi-omics-based Immunometabolic Classification of Lung Squamous Cell Carcinoma and the Mechanism of the XBP1-WNT10A Axis Drivers Myofibroblast Reprogramming to Reshape an Immunosuppression Microenvironment

  • First author: Professor Wei Zhuang, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  • Corresponding author: Professor Jie Wang, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

5. The Prognostic Value of Molecular Residual Disease (MRD) Clearance After Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer: A Prospective Longitudinal Study

  • First author: Professor Yaru Tian, Shandong Cancer Hospital
  • Corresponding author: Professor Hui Zhu, Shandong Cancer Hospital

6. ET-SPACE: Near-Infrared Whole-Body Hyperthermia Combined with Immune Checkpoint Inhibition and RTK Inhibition for Metastatic Castration-Resistant Prostate Cancer: A Single-Center, Open-Label, Randomized Controlled Trial

  • First author: Professor Pengyuan Liu, Zhejiang Hospital, Zhejiang University School of Medicine
  • Corresponding author: Professor Zhibing Wu, Zhejiang Hospital, Zhejiang University School of Medicine

7. EMERALD-3: Tumor Response And Disease Progression Per RECIST v1.1 And mRECIST In The Phase 3 EMERALD-3 Study Of Tremelimumab Plus Durvalumab With Or Without Lenvatinib Plus Transarterial Chemoembolization (TACE) In Embolization-Eligible Hepatocellular Carcinoma

  • First and corresponding author: Academician Jia Fan, Zhongshan Hospital, Fudan University

8. ZG006-003: A phase II dose-optimization study of alveltamig (ZG006) in patients with advanced neuroendocrine carcinoma who have received two or more lines of treatment

  • First author: Professor Chuanhua Zhao, Chinese PLA General Hospital
  • Corresponding author: Professor Jianming Xu, Chinese PLA General Hospital

9. Adjuvant Zoledronic Acid Reduces Recurrence and Improves Disease-Free Survival in Breast Malignant Phyllodes Tumors via Suppressing CREB1-PLK1: A Phase 2 Trial

  • First and corresponding author: Professor Yan Nie, Sun Yat-sen Memorial Hospital, Sun Yat-sen University

10. NDRG1-Targeted Nanocarrier Enhances Radiofrequency Ablation Efficacy in Hepatocellular Carcinoma Through Ferroptosis Amplification and Immune Remodeling

  • First author: Professor Yajie Wang, Zhongda Hospital, Southeast University
  • Corresponding author: Academician Gaojun Teng, Zhongda Hospital, Southeast University

2026 Outstanding Young Scholar Award: 13 Recipients

  • Professor David Chen — Cancer Hospital, Shandong First Medical University
  • Professor Jiujie Cui — Renji Hospital, Shanghai Jiao Tong University School of Medicine
  • Professor Qiang Gao — Zhongshan Hospital, Fudan University
  • Professor Jianbin Li — Institute of Biotechnology, Academy of Military Medical Sciences
  • Professor Chang Liu — Peking University Cancer Hospital
  • Professor Siyang Liu — Guangdong Provincial People’s Hospital
  • Professor Bin Lian — Peking University Cancer Hospital
  • Professor Jie Mei — Nanjing University of Chinese Medicine
  • Professor Jia Zhong — Cancer Hospital, Chinese Academy of Medical Sciences
  • Professor Meng Wu — Peking University Cancer Hospital
  • Professor Chen Xun — The First Affiliated Hospital of China Pharmaceutical University
  • Professor Junli Xue — Shanghai Tenth People’s Hospital
  • Professor Yuxi Zhao — Cancer Hospital, Chinese Academy of Medical Sciences

2026 Academic Collaboration Award: 10 Organizations

  1. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  3. Qilu Pharmaceutical Co., Ltd.
  4. Roche Pharmaceuticals (Shanghai) Co., Ltd.
  5. AstraZeneca Wuxi Trade Co., Ltd.
  6. CSPC Pharmaceutical Group Limited
  7. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  8. MSD (China) Investment Co., Ltd.
  9. BeiGene (Shanghai) Biotechnology Co., Ltd.
  10. Shenyang Sunshine Pharmaceutical Co., Ltd.
Views: 26